CareDx
Contact: Marissa Dixon
3260 Bayshore Blvd
Brisbane
CA
94005
United States
Tel: 415-287-2554
Website: www.caredx.com
Email: mdixon@caredx.com
4 articles about CareDx
-
CareDx Presents Landmark KOAR-1000 Data, Demonstrating Higher 1-Year Graft Survival and Reduction in Biopsies through ARTS SurveillanceKOAR is the largest prospective validation study on AlloSure surveillance with over 1,500 patients enrolled
6/7/2021
CareDx, Inc. announced an analysis of one-year data from the first 1000 patients enrolled in the Kidney Outcomes with AlloSure Registry will be presented at the American Transplant Congress 2021, which is taking place between June 4-9, 2021.
-
CareDx Reports Preliminary Third Quarter 2020 Revenue
10/7/2020
CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced preliminary unaudited revenue for the three months ended September 30, 2020. Preliminary revenue for the three months ended September 30, 2020 is expected to be approximately $53.0 million
-
Natera Files False Advertising Counterclaim Against CareDx
2/18/2020
CareDx's advertising obfuscates AlloSure's poor performance
-
National Kidney Foundation Applauds CareDx® for New Living Donor Employee Recovery Policy
6/5/2018
Offering paid leave for living donation helps remove financial barriers